Access and Utilization of New Antidepressant and Antipsychotic Medications. A. Pharmaceutical Companies

01/01/2000

Pharmaceutical manufacturers were selected based on the following criteria: 1) medium to large size company; and 2) company has current products and products in development in the area of newer atypical antidepressants and/or antipsychotics. As a result, Janssen, AstraZeneca, Eli Lilly, and GlaxoWellcome (GW) were selected.(1) GW and Eli Lilly are both large companies with current pharmaceuticals directed toward treating depression. Eli Lilly also has an atypical antipsychotic on the market to treat schizophrenia. Medium-sized firms include AstraZeneca and Janssen, both of which offer atypical antipsychotics to treat schizophrenia. Specialized neuropharmaceutical companies (e.g., Neurogen) do not have products in development beyond Phase I, and were excluded for this reason. 1

1 One pharmaceutical company is not listed for confidentiality reasons.

Originator Name Current Indications Phase III Mechanism of Action
Large Pharmaceutical Companies
Glaxo Wellcome Wellbutrin®
  • Depression
  • Smoking Cessation
  Unknown
Eli Lilly and Company Prozac®
  • Depression
  • OCD
  • Panic Disorder
Selective serotonin reuptake inhibitor (SSRI)
Zyprexa® (olanzapine)
  • Schizophrenia
  • Bipolar depression
  • Mood stabilization
  • Alzheimer's psychoses
  • Parkinson's disease
Multiple
Medium Sized Pharmaceutical Companies
AstraZeneca Seroquel®
  • Schizophrenia
  Unknown
Janssen Risperdal®
  • Schizophrenia
  Unknown